Morgan Stanley analyst Kallum Titchmarsh downgraded Nevro (NVRO) to Underweight from Equal Weight with a price target of $4, down from $9. Despite noting that the stock is trading around all-time lows, the firm expects spinal cord stimulation demand to remain soft and sees little room for cost cutting, the analyst tells investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVRO: